XOMA Completes Acquisition of Mural Oncology at $2.035 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: Newsfilter
- Acquisition Completed: XOMA Royalty has successfully completed its acquisition of Mural Oncology, with a cash consideration of $2.035 per share, marking a significant expansion in the biotech sector for the company.
- Shareholder Approval: The acquisition received approval from Mural shareholders, indicating market confidence in the transaction, which is expected to enhance XOMA's asset portfolio and future revenue potential.
- Legal Process Smooth: The acquisition was sanctioned by the Irish High Court, ensuring the legality and smooth execution of the transaction, providing XOMA with a solid legal foundation.
- Market Impact: Mural shares will cease trading on Nasdaq immediately following the completion of the acquisition, which is anticipated to positively influence XOMA's market performance and strengthen its competitive position in the biotech industry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
